Since our founding in 2007, Torreya has become a leading financial advisor on life sciences transactions around the globe and across life sciences sectors and therapeutic areas. We have closed over $100 billion worth of deals across nearly 250 assignments.
|
| Acquired by |
|
|
Pending
Up to CHF105 million + 1/3 of future net proceeds from a PRV sale September 2022
|
|
| Advisor on direct public offering |
|
|
September 2022
|
|
| Recommended cash acquisition by |
|
|
Pending
£48.3 million August 2022
|
|
| Investment by |
|
|
£18 million
August 2022
|
|
| Acquired by |
|
|
August 2022
|
|
| In-licensing of global rights to AVTX-007 from |
|
|
Up to $89 million
August 2022
|
|
| Global collaboration for the development and commercialization of ODM-208 with |
|
|
$290 million upfront
July 2022
|
|
| Investment by |
|
|
$68 million
June 2022
|
|
| Sale to |
|
|
$73 million
May 2022
|
|
| Licensing of LM-302 to |
|
|
Up to $1.2 billion in milestones + royalties ($25 million upfront)
May 2022
|
|
| Sale of U.S. manufacturing facility and long-term supply agreement with |
|
|
$44.5 million
April 2022
|
|
| Acquisition of Serenity LLC and global rights to Noctiva™ |
|
|
$41 million + milestones and royalties
March 2022
|
|
| Global multi-target collaboration to discover and develop TCR immunotherapies; acquisition of PRAME TCR |
|
|
€26 million upfront
February 2022
|
|
| Investment by |
|
|
January 2022
|
|
| Investment by |
|
|
December 2021
|
|
| Exclusive licensing and strategic partnership for AB-729 in China with |
|
|
$55 million (upfront + equity)
+ $245 million in milestones December 2021
|
|
| Licensing of Budesolv in China to |
|
|
October 2021
|
|
| Sale of domestic brands to |
|
|
September 2021
|
|
| Acquired by |
|
|
Up to $180 million
September 2021
|
|
| Sale of E7777 to |
|
|
$40 million upfront + $76mm milestones
September 2021
|
|
| License agreement for GnRH antagonist Linzagolix in China from |
|
|
September 2021
|
|
| Investment by |
|
|
$13.5 million
August 2021
|
|
| Acquired by |
|
|
August 2021
|
|
| Sale to |
|
|
$260 million
August 2021
|
|
|
| Sale of U.S. and Canadian rights for ELYXYB to |
|
|
August 2021
|
|
| Out-license of specialty therapy for IgA Nephropathy in Europe to |
|
|
Up to €97.5 million
plus royalties July 2021
|
|
| Sale of non-core UK Specials manufacturing and Aseptic compounding business to |
|
|
June 2021
|
|
| Out -license of Bredinin™ in Mainland China to |
|
|
June 2021
|
|
| Sale of intellectual property to |
|
|
June 2021
|
|
| Management buyout of |
|
|
June 2021
|
|
| Sale to |
|
|
June 2021
|
|
| Sale of 100% equity stake to |
|
|
|
$106 million + milestones
June 2021
|
|
| Series E equity financing |
|
|
|
$104 million
May 2021
|
|
| R&D collaboration agreement with |
|
|
February 2021
|
|
| Equity investment from |
|
|
$200 million
February 2021
|
|
| License of Ravicti® in the Greater China Area, South Korea and Southeast Asia by |
|
|
December 2020
|
|
| License of Galinpepimut-S in Greater China by |
|
|
Up to $202 million with $7.5 million upfront
December 2020
|
|
| Equity Financing Round |
|
|
|
€44.5 million
October 2020
|
|
| Acquired by |
|
|
October 2020
|
|
| Advisor to the Special Committee of the Board of Directors in its merger with |
|
|
$1.5 billion
October 2020
|
|
| Acquisition of |
|
|
$225 million
September 2020
|
|
| Exclusive license agreement to commercialize Triferic® in South Korea with |
|
|
September 2020
|
|
| Sale of Noden to |
|
|
Up to $52.83 Million
September 2020
|
|
| Co-advisor on direct public offering |
|
|
|
$15 million
August 2020
|
|
| Acquisition of Akorn India Limited, a subsidiary of |
|
|
August 2020
|
|
| License of Vicineum™ in Greater China Region to |
|
|
|
$12 million upfront
July 2020
|
|
|
| Disposal of stake in |
|
|
$68 million
May 2020
|
|
| Sale of majority stake to |
|
|
$100 million
May 2020
|
|
| License of Ryaltris™ in the US to |
|
|
February 2020
|
|
|
| Strategic investment from |
|
|
$30 million
February 2020
|
|
| Debt financing by |
|
|
$57.5 million
February 2020
|
|
| Investment by |
|
|
January 2020
|
|
|
| collaboration for its gynecological business in Nepal and India with |
|
|
January 2020
|
|
| License of Navicixizumab to |
|
|
Up to $306 million
January 2020
|
|
| License of Feraccru® in China to |
|
|
$62.8 million
January 2020
|
|
| License of NOV03 in North America to |
|
|
December 2019
|
|
| Acquired by |
|
|
November 2019
|
|
| Company sale to |
|
|
$21.5 million
August 2019
|
|
| Sale of two orphan drug programs to |
|
|
August 2019
|
|
| License of Gemcabene in China to |
|
|
July 2019
|
|
| Growth financing with |
|
|
June 2019
|
|
|
| License of Nefecon in Greater China and Singapore to |
|
|
Up to $121 million
June 2019
|
|
| Majority recap by |
|
|
$125 million
April 2019
|
|
| Venture debt raise with |
|
|
$20 million
April 2019
|
|
| Financing with |
|
|
$40 Million
March 2019
|
|
|
| BE Vaccines SAS sale to Clean Cells, a portfolio company of |
|
|
Undisclosed
March 2019
|
|
| Sale of stock and conditional sale to |
|
|
$215 million + CVRs
February 2019
|
|
| Sale of majority stake to |
|
|
February 2019
|
|
| Credit facility from |
|
|
$70 million
January 2019
|
|
| Research collaboration and license agreement for RIG-I pathway with |
|
|
Up to $505 million
December 2018
|
|
|
| JV Partnership in China with |
|
|
$50 million
December 2018
|
|
and purchase of majority stake in |
|
|
December 2018
|
|
| License of Durasert™ in Ophthalmology in the Greater China Region to |
|
|
Up to $11.75 million
November 2018
|
|
| Sale of Midatech Pharma US Inc. to Kanwa Holdings LP, an affiliate of Barings LLC |
|
|
|
Up to $19 million
November 2018
|
|
| Sale of Sevelamer ANDA to |
|
|
October 2018
|
|
| Licensing of ex European rights for LYS-SAF302 to |
|
|
Up to $125 Millionwith committed payments of $29m plus royalties
October 2018
|
|
| Debt recapitalization and acquisition of NextWave Pharmaceuticals from |
|
|
|
$125 million
September 2018
|
|
| Acquires royalty interest position for 7 assets from |
|
|
$15 million
September 2018
|
|
|
| Licensing agreement for Feraccru® in Europe, Australia and New Zealand with |
|
|
£11 million upfront(plus up to £54.5m in milestones and 25-40% royalties)
September 2018
|
|
| License of AJT-240 in hemodialysis in China to |
|
|
Up to $24 million
June 2018
|
|
| Partial royalty monetization with |
|
|
$7.5 Million
June 2018
|
|
| Term loan from |
|
|
$40 Million
June 2018
|
|
| sale of Yargesa to |
|
|
June 2018
|
|
| License and collaboration agreement for global rights for LPA receptor program with |
|
|
Up to $200 million
May 2018
|
|
| Debt financing for acquisition of Icon Biosciences from |
|
|
|
$20 Million
March 2018
|
|
| Majority recap by |
|
|
March 2018
|
|
|
| Sale of consumer products to |
|
|
February 2018
|
|
|
| Sale of ANDA portfolio to |
|
|
January 2018
|
|
| Sale to |
|
|
January 2018
|
|
|
| Loan agreement with |
|
|
$15 Million
January 2018
|
|
|
| Sale of OTC portfolio to |
|
|
December 2017
|
|
| Acquisition of API facility from |
|
|
December 2017
|
|
| Sale of majority equity stake to |
|
|
December 2017
|
|
| Sale to |
|
|
Up to $34 million
November 2017
|
|
| Merger with |
|
|
$34.9 million
November 2017
|
|
|
| License of Gevokizumab and certain associated IP to |
|
|
$31 million upfront
August 2017
|
|
|
| Sale of generics portfolio to |
|
|
$18 million
August 2017
|
|
| Asset sale to |
|
|
July 2017
|
|
|
| Sale of selected generic brands to |
|
|
June 2017
|
|
| Sale of company to |
|
|
June 2017
|
|
| Acquisition of generics business of |
|
|
$1.05 billion
June 2017
|
|
| Company sale to |
|
|
June 2017
|
|
| License of US rights to Posimir® to |
|
|
|
$293 million
May 2017
|
|
| Sale of stake of |
|
|
$35 million
Joint Sell-Side Advisor May 2017
|
|
| Acquisition of phase III royalty interest |
|
|
May 2017
|
|
| Sale of US dermatology business to |
|
|
$13.6 million
May 2017
|
|
|
| Sale of India women's health business to |
|
|
|
April 2017
|
|
| Sale of Intrathecal business to |
|
|
|
$203 million
March 2017
|
|
| Company sale to |
|
|
$35.9 million
March 2017
|
|
|
| Acquired SLO Niacin® from |
|
|
|
March 2017
|
|
|
| Licensed Nexafed® from |
|
|
March 2017
|
|
| Microbiome partnership with |
|
|
$2.6 billion
($50 million upfront) January 2017
|
|
|
| Sale of royalties to |
|
|
$22 million
December 2016
|
|
| Sale of royalties to |
|
|
|
$17.5 million
December 2016
|
|
| Merger with |
|
|
$251 million
December 2016
|
|
| Collaboration agreement for Emricasan with |
|
|
|
$50 million upfront
December 2016
|
|
| Has merged with Aspen Park Pharma to form |
|
|
November 2016
|
|
| Company sale to |
|
|
> €75 million
November 2016
|
|
| Sale of equity stake to |
|
|
$33 million
November 2016
|
|
|
| Sale of ANDA portfolio to |
|
|
|
October 2016
|
|
| Partial sale of royalty and milestones |
|
|
|
$40 million
September 2016
|
|
| Partial royalty and milestone sale to |
|
|
|
$6 million
August 2016
|
|
| Sale of phase II enzyme replacement royalty |
|
|
|
August 2016
|
|
| Sale of majority stake to |
|
|
July 2016
|
|
| Licensing of Dalbavancin from |
|
|
|
$13 million upfront
May 2016
|
|
| License of milk allergy product to |
|
|
€100 million
May 2016
|
|
| Sale and contribution of orphan disease asset to |
|
|
May 2016
|
|
|
| US license agreement for NATESTO® to |
|
|
Up to $45.5 million
($8 million upfront) April 2016
|
|
| Sale of Akarx to |
|
|
March 2016
|
|
| Advisory to ownership group on sale to |
|
|
March 2016
|
|
|
| Sale of abbreviated new drug applications |
|
|
|
February 2016
|
|
| Sale of assets to |
|
|
$10 million
February 2016
|
|
|
| Royalty-backed acquisition financing for undisclosed spec pharma |
|
|
|
$100 million
February 2016
|
|
| Preferred equity investment |
|
|
|
$7 million
January 2016
|
|
| Sale to |
|
|
|
Up to $45 million
($16 million upfront) December 2015
|
|
| Company sale to |
|
|
$100+ million
December 2015
|
|
|
| Acquisition of |
|
|
Up to $30 million
December 2015
|
|
| Senior term loan |
|
|
|
$15 million
December 2015
|
|
|
| Sale of biologics manufacturing facilities to |
|
|
|
$5 million in cash +
$1 million in stock November 2015
|
|
| Acquisition of |
|
|
CAD $47 million
October 2015
|
|
|
| License of global rights for Anti-TGF-beta antibody program to |
|
|
|
Up to $517 million
October 2015
|
|
| Debt financing from |
|
|
|
$20 million
September 2015
|
|
| Sale to |
|
|
|
Up to $605 million
July 2015
|
|
|
| Sale of abbreviated new drug application portfolio to |
|
|
|
$25 million +
profit share July 2015
|
|
| Sale to |
|
|
|
June 2015
|
|
| License of preclinical derm antibody to |
|
|
Up to €105 million
May 2015
|
|
| Acquisition of |
|
|
Up to €50 million
May 2015
|
|
|
| Sale of Zonalon® to |
|
|
March 2015
|
|
| Sale of FXR program to |
|
|
Up to $470 million
January 2015
|
|
| License of naloxone opioid overdose reversal treatment to |
|
|
$55+ million
December 2014
|
|
| License of antimicrobial technology to |
|
|
December 2014
|
|
| Sale of Pessac plant to |
|
|
Up to €22 million
November 2014
|
|
|
| Divestiture of certain abbreviated new drug applications to |
|
|
Up to $18 million
October 2014
|
|
| Acquisition of |
|
|
Up to $35 million
October 2014
|
|
|
| Acquisition financing from |
|
|
|
$20 million
October 2014
|
|
| Financial advisor on IPO |
|
|
|
$30 million
October 2014
|
|
| License of Pidilizumab to |
|
|
Up to $335 million
with royalty October 2014
|
|
|
| Global offering advisory |
|
|
|
$133 million
October 2014
|
|
| Synthetic royalty financing from |
|
|
|
$10 million
October 2014
|
|
| Sale to |
|
|
$65 million
September 2014
|
|
| Acquisition of Canadian rights to Estrace® from |
|
|
$41 million
July 2014
|
|
|
| Loan from |
|
|
|
$25 million
July 2014
|
|
| Merger with |
|
|
|
$24 million
July 2014
|
|
| Sale to |
|
|
$658 million
June 2014
|
|
| Sale to |
|
|
|
$75 million upfront + milestones
May 2014
|
|
| Acquisition of Donnatal® from |
|
|
$328 million
May 2014
|
|
| Financial advisor on follow-on offering |
|
|
|
$72.5 million
February 2014
|
|
| Sale of substantially all assets to |
|
|
February 2014
|
|
| Sale to |
|
|
|
$40+ million with
$10 million upfront January 2014
|
|
|
| Sale of 31 abbreviated new drug applications to |
|
|
|
$12.5 million +
profit share December 2013
|
|
| Sale to |
|
|
|
December 2013
|
|
| License of chemotherapy benefit test for high risk breast cancer to |
|
|
$9 million + milestones and royalties
November 2013
|
|
| Sale to |
|
|
|
19.9% of shares +
$12 million November 2013
|
|
|
| Financial advisor in private placement |
|
|
|
€29.9 million
November 2013
|
|
| Sale of Naprelan® to |
|
|
November 2013
|
|
| Merger into |
|
|
September 2013
|
|
|
| Advisor on oncology partnership with |
|
|
|
$550 million with
$10 million upfront August 2013
|
|
| Sale of vaccine company to |
|
|
$250 million with
$35 million upfront May 2013
|
|
|
| Divestiture of three pediatric drugs to |
|
|
|
$28.7 million
May 2013
|
|
|
| Sale of basket of royalties to |
|
|
$6 million upfront
April 2013
|
|
| Acquisition of EU rights to Vibativ® from |
|
|
$5 million + royalties
March 2013
|
|
| Sale for up to $106 million to |
|
|
$12 million +
milestones January 2013
|
|
| Collaboration with |
|
|
|
December 2012
|
|
| Sale of Fareston® to |
|
|
$21.7 million
October 2012
|
|
| Sale of Amicar® rights to |
|
|
August 2012
|
|
|
| Divestiture of Cuvposa® to |
|
|
August 2012
|
|
|
| Sale of Roxicodone® to |
|
|
August 2012
|
|
|
| Sale of Zipsor® to |
|
|
June 2012
|
|
| Structured debt transaction linked to three pharma royalties |
|
|
$65 million
December 2011
|
|
| Sale to |
|
|
$10 million +
milestones October 2011
|
|
|
| Sale of prenatal vitamin franchise |
|
|
|
October 2011
|
|
|
| Financial advisor in follow-on financing for GI company |
|
|
|
July 2011
|
|
| Sale of Canadian biotechnology company to |
|
|
May 2011
|
|
|
| Co-promotion for Zipsor® |
|
|
May 2011
|
|
|
| Sale of royalties for Cubicin® and Lexiscan® to |
|
|
$487 million
April 2011
|
|
|
| Advisor in iSonep license to |
|
|
|
$500 million with
$14 million upfront December 2010
|
|
| Sale of dermatology specialty pharma business to |
|
|
December 2010
|
|
| Sale to |
|
|
$100+ million
October 2010
|
|
| Advisor in the acquisition of six products from |
|
|
July 2010
|
|
| Sale of Crinone® & Prochieve® product lines and shares to |
|
|
$92.5 million with
$47 million upfront July 2010
|
|
| Acquisition of |
|
|
$40 million +
milestones June 2010
|
|
| Advisor to Genentech major shareholder in sale to |
|
|
$46 billion
March 2009
|
|
| Sale to |
|
|
September 2008
|
|
| Sale to |
|
|
April 2008
|